# Slowing Disability in MS

Page: https://stenobird.com/podcast/the-bio-report-1092382/slowing-disability-in-ms
Text version: https://stenobird.com/podcast/the-bio-report-1092382/slowing-disability-in-ms.md
Podcast: [The Bio Report](https://stenobird.com/podcast/the-bio-report-1092382)
Published: 2026-04-22T07:00:00+00:00
Episode link: https://thebioreport.podbean.com/e/slowing-disability-in-ms/
Audio file: https://mcdn.podbean.com/mf/web/m7ej46bny599zbh4/BR-Daniel_Vitt-4-22-26apux5.mp3
Processing state: not_requested
JSON: https://stenobird.com/v1/public/podcasts/the-bio-report-1092382/episodes/slowing-disability-in-ms
Duration seconds: 1758

## Resource

Most existing therapies for multiple sclerosis do a good job of reducing relapses and inflammatory activity, but they largely fail to stop the slow neurodegeneration that drives long-term disability, especially in progressive forms of the disease. Immunic Therapeutics is trying to reshape the treatment landscape for multiple sclerosis with its experimental once-daily oral therapy, designed not only to curb inflammation and relapses but also to tackle the neurodegeneration that silently drives disability progression in both relapsing and progressive forms of MS. Daniel Vitt, CEO of Immunic, discusses how the company’s experimental MS therapy works, how it may protect neurons from cell death, and the potential for its dual mechanism of action to change the treatment landscape.

## Actions

- request_transcript: `POST https://stenobird.com/v1/public/podcasts/the-bio-report-1092382/episodes/slowing-disability-in-ms/transcription-requests` — Idempotently request low-priority transcript generation for this episode.
- read_markdown: `GET https://stenobird.com/podcast/the-bio-report-1092382/slowing-disability-in-ms.md` — Read the agent-friendly Markdown representation of this episode resource.

A page view does not enqueue transcription. Agents should invoke `request_transcript` explicitly when they need this episode processed.

## Transcript

Full transcripts are not published on public pages unless there is a clear rights basis.